Nymox Pharmaceutical Corp. reported statistically significant results from phase 3 trials of fexapotide triflutate to treat prostate enlargement and prostate cancer.
According to the results, patients treated with the drug exhibited indications of sexual function improvement.
The first-line previous treatment-naive patients showed statistically significant improvements from baseline compared to the lack of improvements in the placebo group one year after treatment.
Fexapotide-treated subjects had statistically significant improvement compared to placebo, while placebo-treated patients also experienced worsening of sexual function.
Nymox initially reported the absence of significant sexual or other side-effects from the drug based on 15 years of clinical research in prospective randomized trials in the U.S.
The company submitted a marketing approval application in Europe for the drug May 3.